No Image

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verb Technology Company, Inc.

August 19, 2019 Globe Newswire 0

LOS ANGELES, Aug. 19, 2019 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 9, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Verb Technology Company, Inc. …

The post Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verb Technology Company, Inc. appeared first on Wolfe’s Blog.

No Image

Vera Bradley Co-Founder Patricia R. Miller Announces Retirement From the Company’s Board of Directors

August 19, 2019 Globe Newswire 0

FORT WAYNE, Ind., Aug. 19, 2019 (GLOBE NEWSWIRE) — Vera Bradley (NASDAQ:VRA) (the “Company”) today announced co-founder and long-time board member Patricia R. Miller is retiring from the Company’s board of directors, effective August 30, 2019.

Miller and close friend Barbara Bradley Baekgaard co-founded Vera Bradley in 1982, and Miller has served as a member of the Company’s board of directors since then. From 1982 through June 2010, she served as Co-President of the Company. In June 2010, she was appointed National Spokesperson for the Company where she continued to promote the brand until her retirement in October 2012.

Miller took a leave of absence from the Company in 2005 and 2006 to serve as the first Secretary of Commerce for the State of Indiana and the Chief Executive Officer of the Indiana Economic Development Corporation.  

In 1994, the loss of a dear friend to breast cancer inspired Miller and Baekgaard to add a new dimension to Vera Bradley, establishing the Vera Bradley Foundation for Breast Cancer. To date, the Foundation has raised over $32 million for breast cancer research at the Indiana University Melvin and Bren Simon Cancer Center.

In addition to serving on the board of the Vera Bradley Foundation for Breast Cancer, Miller serves as a director for the Indiana University Foundation, and in the past, she has served as a board member for more than 15 non-profit organizations. Miller has received numerous awards including the Entrepreneur of the Year Award for the State of Indiana from Arthur Young/VENTURE in 1987 (awarded jointly with Baekgaard), the Indiana Commission for Women Torchbearer Award for Business in 2007, the Indiana …

Full story available on Benzinga.com

The post Vera Bradley Co-Founder Patricia R. Miller Announces Retirement From the Company’s Board of Directors appeared first on Wolfe’s Blog.

No Image

FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA

August 19, 2019 Globe Newswire 0

NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from August 4, 2017 through May 10, 2019, inclusive (the “Class Period”) of the important August 20, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.

To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1609.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Full story available on Benzinga.com

The post FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA appeared first on Wolfe’s Blog.

No Image

FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA

August 19, 2019 Globe Newswire 0

NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from August 4, 2017 through May 10, 2019, inclusive (the “Class Period”) of the important August 20, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.

To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1609.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Full story available on Benzinga.com

The post FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA appeared first on Wolfe’s Blog.

No Image

27 Technology Stocks Moving In Monday’s Pre-Market Session

August 19, 2019 Lisa Levin 0

Gainers

  • Huami, Inc. (NYSE: HMI) shares rose 9.7% to $12.30 during Monday’s pre-market session. The market value of their outstanding shares is at $442.9 million.
  • Weibo, Inc. (NASDAQ: WB) shares increased by 8.4% to $40.20. The market cap stands at $7.8 billion. The most recent rating by Jefferies, on August 05, is at Hold, with a price target of $43.60.
  • SINA, Inc. (NASDAQ: SINA) shares increased by 6.8% to $40.19. The market cap seems to be at $6.0 billion. According to the most recent rating by Jefferies, on August 05, the current rating is at Hold.
  • Vislink Technologies, Inc. (NASDAQ: VISL) stock rose 6.8% to $0.87. The market cap stands at $9.0 million.
  • Sonos, Inc. (NASDAQ: SONO) shares increased by 6.1% to $12.64. According to the most recent rating by Raymond James, on August 19, the current rating is at Strong Buy.
  • Digital Turbine, Inc. (NASDAQ: APPS) stock surged 5.7% to $6.89. The market cap stands at $106.7 million. The most recent rating by Canaccord Genuity, on June 27, is at Buy, with a price target of $6.00.
  • ON Semiconductor, Inc. (NASDAQ: ON) shares moved upwards by 4.9% to $18.40. The market cap stands at $9.0 billion. The most recent rating by Raymond James, on August 19, is at Strong Buy, with a price target of $21.00.
  • iQIYI, Inc. (NASDAQ: IQ) shares rose 4.3% to $17.82. The market cap seems to be at $12.1 billion. The most recent rating by JP Morgan, on August 16, is at Underweight, with a price target of $14.00.
  • Inpixon, Inc. (NASDAQ:

Full story available on Benzinga.com

The post 27 Technology Stocks Moving In Monday’s Pre-Market Session appeared first on Wolfe’s Blog.

No Image

8 Energy Stocks Moving In Monday’s Pre-Market Session

August 19, 2019 Lisa Levin 0

Gainers

  • Denbury Resources, Inc. (NYSE: DNR) shares rose 3.8% to $1.09 during Monday’s pre-market session. The market cap stands at $5.9 billion.
  • Range Resources, Inc. (NYSE: RRC) shares increased by 3.2% to $4.24. The market cap seems to be at $3.8 billion. According to the most recent rating by MKM Partners, on August 19, the current rating is at Buy.
  • Tenaris, Inc. (NYSE: TS) stock moved upwards by 2.3% to $21.83. The market cap seems to …

Full story available on Benzinga.com

The post 8 Energy Stocks Moving In Monday’s Pre-Market Session appeared first on Wolfe’s Blog.

No Image

7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sunlands Technology Group and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

August 19, 2019 Globe Newswire 0

LOS ANGELES, Aug. 19, 2019 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sunlands Technology Group (“Sunlands” or “the Company”) (NYSE: STG) for violations of the federal securities laws.

Investors who purchased the Company’s shares pursuant to and/or traceable to the Company’s Initial Public Offering in March 2018 (the “IPO”) are encouraged to contact the firm before August 26, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also …

Full story available on Benzinga.com

The post 7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sunlands Technology Group and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm appeared first on Wolfe’s Blog.

No Image

33 Healthcare Stocks Moving In Monday’s Pre-Market Session

August 19, 2019 Lisa Levin 0

Gainers

  • Miragen Therapeutics, Inc. (NASDAQ: MGEN) shares moved upwards by 17.6% to $1.07 during Monday’s pre-market session. The most recent rating by H.C. Wainwright, on August 19, is at Buy, with a price target of $3.00.
  • Moleculin Biotech, Inc. (NASDAQ: MBRX) stock increased by 13.2% to $1.20. The market cap seems to be at $40.3 million.
  • Co-Diagnostics, Inc. (NASDAQ: CODX) shares increased by 10.6% to $1.25. The market cap seems to be at $35.7 million.
  • TrovaGene, Inc. (NASDAQ: TROV) shares moved upwards by 10.1% to $2.30.
  • Solid Biosciences, Inc. (NASDAQ: SLDB) shares rose 9.7% to $9.66. The market cap seems to be at $321.5 million. According to the most recent rating by SVB Leerink, on August 19, the current rating is at Outperform.
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) stock rose 8.7% to $2.63. The market cap seems to be at $4.8 billion. The most recent rating by BMO Capital, on August 06, is at Market Perform, with a price target of $5.00.
  • Check-Cap, Inc. (NASDAQ: CHEK) shares surged 8.2% to $2.10. The market cap seems to be at $32.7 million.
  • Genfit, Inc. (NASDAQ: GNFT) shares rose 7.5% to $16.97. The market cap stands at $638.7 million.
  • Pluristem Therapeutics, Inc. (NASDAQ: PSTI) stock surged 6.9% to $3.87. The market cap seems to be at $134.3 million.
  • Jaguar Health, Inc. (NASDAQ: JAGX) shares surged 6.3% to $1.18.
  • HEXO, Inc. (NYSE: HEXO) shares rose 5.7% to $4.70. The market cap …

Full story available on Benzinga.com

The post 33 Healthcare Stocks Moving In Monday’s Pre-Market Session appeared first on Wolfe’s Blog.

No Image

12 Industrials Stocks Moving In Monday’s Pre-Market Session

August 19, 2019 Lisa Levin 0

Gainers

  • DryShips, Inc. (NASDAQ: DRYS) stock moved upwards by 35.8% to $5.20 during Monday’s pre-market session. The market cap stands at $318.8 million.
  • TOP Ships, Inc. (NASDAQ: TOPS) stock surged 10.5% to $0.36. The market cap stands at $20.0 million.
  • Frontline, Inc. (NYSE: FRO) stock increased by 7.1% to $7.51.
  • Seanergy Maritime Hldgs, Inc. (NASDAQ: SHIP) stock surged 5.5% to $0.58. The market cap stands at $38.9 million.
  • CNH Industrial, Inc. (NYSE: CNHI) stock rose 3.9% to $9.16. The market value of their outstanding shares is at $12.4 billion. According to the most recent rating by Morgan Stanley, on August 19, the …

Full story available on Benzinga.com

The post 12 Industrials Stocks Moving In Monday’s Pre-Market Session appeared first on Wolfe’s Blog.

No Image

7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against EQT Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

August 19, 2019 Globe Newswire 0

LOS ANGELES, Aug. 19, 2019 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against EQT Corporation (“EQT” or “the Company”) (NYSE: EQT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between June 19, 2017 and October 24, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before August 26, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park …

Full story available on Benzinga.com

The post 7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against EQT Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Diebold Nixdorf, Inc. (NYSE:DBD), Intelligent Systems Corporation (NYSE:INS), Helius Medical Technologies, Inc. (NASDAQ:HSDT), and Verb Technology Company, Inc. (NASDAQ:VERB). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Diebold Nixdorf, Inc. (NYSE:DBD)

Lead Plaintiff Deadline: September 3, 2019

Class Period: February 14, 2017 to July 4, 2017

The complaint, filed on July 2, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was experiencing delays in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle; (ii) the foregoing issues were negatively impacting the Company’s services business and operations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. On July 5, 2017, Diebold disclosed that the Company expected a wider net loss than indicated in its prior guidance for fiscal 2017, from a range of $50 to $75 million to a range of $110 to $125 million net loss.

The Company attributed the lowered expectations to a delay in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle. 6. Following this news, Diebold’s stock price fell $6.40 per share, or nearly 23%, to close at …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Diebold Nixdorf, Inc. (NYSE:DBD), Intelligent Systems Corporation (NYSE:INS), Helius Medical Technologies, Inc. (NASDAQ:HSDT), and Verb Technology Company, Inc. (NASDAQ:VERB). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Diebold Nixdorf, Inc. (NYSE:DBD)

Lead Plaintiff Deadline: September 3, 2019

Class Period: February 14, 2017 to July 4, 2017

The complaint, filed on July 2, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was experiencing delays in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle; (ii) the foregoing issues were negatively impacting the Company’s services business and operations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. On July 5, 2017, Diebold disclosed that the Company expected a wider net loss than indicated in its prior guidance for fiscal 2017, from a range of $50 to $75 million to a range of $110 to $125 million net loss.

The Company attributed the lowered expectations to a delay in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle. 6. Following this news, Diebold’s stock price fell $6.40 per share, or nearly 23%, to close at …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Eagle Bancorp, Inc. (NASDAQ:EGBN), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), L Brands, Inc. (NYSE:LB), and National General Holdings Corp. (NASDAQ:NGHC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Eagle Bancorp, Inc. (NASDAQ:EGBN)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2015 to July 19, 2019

The complaint, filed on July 24, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company to undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 17, 2019, Eagle Bancorp disclosed rising legal costs stemming from ongoing internal and government investigations of “the Company’s identification, classification and disclosure of related party transactions; the retirement of certain former officers and directors; and the relationship of the Company and certain of its former officers and directors with a local public official.”

On this news, Eagle Bancorp’s stock price fell $14.30 per share, or 26.75%, to close at $39.15 per share on July 18, 2019.

For more information on the Eagle Bancorp class action go to: https://bespc.com/EGBN

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2017 to February 22, 2019

The Complaint, filed on July 23, 2019, alleges that during the Class Period defendants falsely represented the safety and efficacy of selinexor, a pharmaceutical drug intended for the treatment of various types of cancer that Karyopharm was in the process of developing. Specifically, defendants’ material misrepresentations and omissions center on defendants’ claims regarding results from clinical trials for selinexor’s treatment of patients with certain types of blood cancer. During the Class Period, defendants claimed that selinexor studies showed that selinexor was “well-tolerated” by patients and explained that …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Eagle Bancorp, Inc. (NASDAQ:EGBN), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), L Brands, Inc. (NYSE:LB), and National General Holdings Corp. (NASDAQ:NGHC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Eagle Bancorp, Inc. (NASDAQ:EGBN)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2015 to July 19, 2019

The complaint, filed on July 24, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company to undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 17, 2019, Eagle Bancorp disclosed rising legal costs stemming from ongoing internal and government investigations of “the Company’s identification, classification and disclosure of related party transactions; the retirement of certain former officers and directors; and the relationship of the Company and certain of its former officers and directors with a local public official.”

On this news, Eagle Bancorp’s stock price fell $14.30 per share, or 26.75%, to close at $39.15 per share on July 18, 2019.

For more information on the Eagle Bancorp class action go to: https://bespc.com/EGBN

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2017 to February 22, 2019

The Complaint, filed on July 23, 2019, alleges that during the Class Period defendants falsely represented the safety and efficacy of selinexor, a pharmaceutical drug intended for the treatment of various types of cancer that Karyopharm was in the process of developing. Specifically, defendants’ material misrepresentations and omissions center on defendants’ claims regarding results from clinical trials for selinexor’s treatment of patients with certain types of blood cancer. During the Class Period, defendants claimed that selinexor studies showed that selinexor was “well-tolerated” by patients and explained that …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE:MNK), Oasmia Pharmaceutical AB (NASDAQ:OASM), Aclaris Therapeutics, Inc. (NYSE:ACRS), and Curaleaf Holdings, Inc. (OTC:CURLF).  Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Mallinckrodt Plc (NYSE:MNK)

Lead Plaintiff Deadline: September 24, 2019

Class Period: February 28, 2018 to July 16, 2019

The complaint, filed on July 26, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 16, 2019, post-market, Mallinckrodt announced that the Company was permanently discontinuing the PENNANT Trial assessing Acthar’s safety and efficacy as an ALS treatment. Mallinckrodt stated that it decided “to halt the trial after careful consideration of a recent recommendation by the study’s independent Data and Safety Monitoring Board” (“DSMB”), which “was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo” and that “the board also mentioned other adverse events specific to this patient population.” On this news, Mallinckrodt’s stock price fell $0.64 per share, or 7.8%, to close at $7.56 per share on July 17, 2019.

For more information on the Mallinckrodt class …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE:MNK), Oasmia Pharmaceutical AB (NASDAQ:OASM), Aclaris Therapeutics, Inc. (NYSE:ACRS), and Curaleaf Holdings, Inc. (OTC:CURLF).  Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Mallinckrodt Plc (NYSE:MNK)

Lead Plaintiff Deadline: September 24, 2019

Class Period: February 28, 2018 to July 16, 2019

The complaint, filed on July 26, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 16, 2019, post-market, Mallinckrodt announced that the Company was permanently discontinuing the PENNANT Trial assessing Acthar’s safety and efficacy as an ALS treatment. Mallinckrodt stated that it decided “to halt the trial after careful consideration of a recent recommendation by the study’s independent Data and Safety Monitoring Board” (“DSMB”), which “was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo” and that “the board also mentioned other adverse events specific to this patient population.” On this news, Mallinckrodt’s stock price fell $0.64 per share, or 7.8%, to close at $7.56 per share on July 17, 2019.

For more information on the Mallinckrodt class …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE:CTST), Realogy Holdings Corporation (NYSE:RLGY), Reckitt Benckiser Group Plc (OTC:RBGLY), and Omnicell, Inc. (NASDAQ:OMCL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

CannTrust Holdings, Inc. (NYSE:CTST)

Lead Plaintiff Deadline: September 9, 2019

Class Period: November 14, 2018 to July 12, 2019

The complaint, filed on July 10, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) that the Company’s Pelham greenhouse did not comply with certain regulations; (3) that, as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) that, as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the CannTrust class action go to: https://bespc.com/ctst

Realogy Holdings Corp. (NYSE:RLGY)

Lead Plaintiff Deadline: …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE:CTST), Realogy Holdings Corporation (NYSE:RLGY), Reckitt Benckiser Group Plc (OTC:RBGLY), and Omnicell, Inc. (NASDAQ:OMCL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

CannTrust Holdings, Inc. (NYSE:CTST)

Lead Plaintiff Deadline: September 9, 2019

Class Period: November 14, 2018 to July 12, 2019

The complaint, filed on July 10, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) that the Company’s Pelham greenhouse did not comply with certain regulations; (3) that, as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) that, as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the CannTrust class action go to: https://bespc.com/ctst

Realogy Holdings Corp. (NYSE:RLGY)

Lead Plaintiff Deadline: …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors

August 17, 2019 Globe Newswire 0

BEIJING, Aug. 17, 2019 (GLOBE NEWSWIRE) — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (Nasdaq GS: CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced changes to the composition of the Company’s Board of Directors (“the Board”).

Ms. Jean Xiaohong Kong and Mr. Yunjie Liu resigned from the management team and the Board on August 15, 2019. Mr. Bin Liu (acting CEO) and Mr. Xiaoqiang Wei (Vice President) were elected to the Board on that same date. In addition, the Board has strengthened its composition with the election of Dong Yu on August 11, 2019, to serve as an independent director of the Company’s Board.

Mr. Dong Yu, a CPA, based in Shanghai, serves as Vice President of Finance, APAC Region for Nexans Cable (China) Co., Limited, a regional subsidiary of Nexans S.A. a global player in the cable and optical fiber industry and second largest global manufacturer of cables. Mr. Yu through his deep experience working …

Full story available on Benzinga.com

The post UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors appeared first on Wolfe’s Blog.

No Image

UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors

August 17, 2019 Globe Newswire 0

BEIJING, Aug. 17, 2019 (GLOBE NEWSWIRE) — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (Nasdaq GS: CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced changes to the composition of the Company’s Board of Directors (“the Board”).

Ms. Jean Xiaohong Kong and Mr. Yunjie Liu resigned from the management team and the Board on August 15, 2019. Mr. Bin Liu (acting CEO) and Mr. Xiaoqiang Wei (Vice President) were elected to the Board on that same date. In addition, the Board has strengthened its composition with the election of Dong Yu on August 11, 2019, to serve as an independent director of the Company’s Board.

Mr. Dong Yu, a CPA, based in Shanghai, serves as Vice President of Finance, APAC Region for Nexans Cable (China) Co., Limited, a regional subsidiary of Nexans S.A. a global player in the cable and optical fiber industry and second largest global manufacturer of cables. Mr. Yu through his deep experience working …

Full story available on Benzinga.com

The post UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors appeared first on Wolfe’s Blog.

No Image

CBP To Start Live Testing Blockchain In IPR Arena

August 16, 2019 FreightWaves 0

Customs and Border Protection late this month will start live testing for blockchain’s applicability to intellectual property rights (IPR) enforcement, according to a document posted online in preparation for the August 21 Commercial Customs Operations Advisory Committee (COAC) meeting in Buffalo, N.Y.

The test is scheduled to last through late September, says the document posted by the COAC Next Generation Facilitation Subcommittee.

Since its last in-person meeting in March, the subcommittee’s Emerging Technology Working Group has “progressed” through the integration of industry and CBP systems for CBP’s ongoing proof of concept (POC) on IPR, the document says.

The POC strives to facilitate shipments based on known licensing relationships through the use of blockchain.

In another document posted in preparation for the COAC meeting, the COAC Trusted Trader Working Group posted additional recommendations related to forced labor for future implementation of the Customs-Trade Partnership Against Terrorism (CTPAT) Trade Compliance program.

The working group posted a first round of forced labor recommendations for CTPAT in February.

Among other things, COAC is recommending that CBP design program requirements to encourage participation to facilitate self-identification of low-risk importers; that CBP and stakeholders hold informal meetings to learn about typical corporate social responsibility programs; and that …

Full story available on Benzinga.com

The post CBP To Start Live Testing Blockchain In IPR Arena appeared first on Wolfe’s Blog.

No Image

CBP To Start Live Testing Blockchain In IPR Arena

August 16, 2019 FreightWaves 0

Customs and Border Protection late this month will start live testing for blockchain’s applicability to intellectual property rights (IPR) enforcement, according to a document posted online in preparation for the August 21 Commercial Customs Operations Advisory Committee (COAC) meeting in Buffalo, N.Y.

The test is scheduled to last through late September, says the document posted by the COAC Next Generation Facilitation Subcommittee.

Since its last in-person meeting in March, the subcommittee’s Emerging Technology Working Group has “progressed” through the integration of industry and CBP systems for CBP’s ongoing proof of concept (POC) on IPR, the document says.

The POC strives to facilitate shipments based on known licensing relationships through the use of blockchain.

In another document posted in preparation for the COAC meeting, the COAC Trusted Trader Working Group posted additional recommendations related to forced labor for future implementation of the Customs-Trade Partnership Against Terrorism (CTPAT) Trade Compliance program.

The working group posted a first round of forced labor recommendations for CTPAT in February.

Among other things, COAC is recommending that CBP design program requirements to encourage participation to facilitate self-identification of low-risk importers; that CBP and stakeholders hold informal meetings to learn about typical corporate social responsibility programs; and that …

Full story available on Benzinga.com

The post CBP To Start Live Testing Blockchain In IPR Arena appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against FedEx Corporation – FDX

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of FedEx Corporation (NYSE:FDX) from September 19, 2017 through December 18, 2018, inclusive (t…

The post Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against FedEx Corporation – FDX appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Anheuser-Busch InBev SA/NV – BUD

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) from March 1, 2018 through October 24, 2018, inclusive…

The post Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Anheuser-Busch InBev SA/NV – BUD appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against Sunlands Technology Group – STG

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Sunlands Technology Group (NYSE:STG) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Sunlands’s March 2018 initial public stock offering (the “IPO” or the “Offering”). The lawsuit seeks to recover damages for Sunlands investors under the federal securities laws.

If you wish to serve as lead plaintiff, you must move the Court no later than August 26, 2019. A lead plaintiff is a representative party …

Full story available on Benzinga.com

The post Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against Sunlands Technology Group – STG appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Eros International PLC– EROS

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Eros International PLC (NYSE:EROS) from July 28, 2017 through June 5, 2019, inclusive (the “…

The post Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Eros International PLC– EROS appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 19 Deadline in Securities Class Action Lawsuit Pivotal Software, Inc. – PVTL

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Pivotal Software, Inc. (NYSE:PVTL): (1) pursuant and/or traceable to the registration statement and prospectus (the “Registration Statement”) issued in connection with Pivotal’s April 2018 initial public offering (the “IPO”); and/or (2) between April 24, 2018 and June 4, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Pivotal investors under the federal securities laws.

To join the Pivotal class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=pivotal-software-inc&id=1914 or call Sophie …

Full story available on Benzinga.com

The post Zhang Investor Law Reminds Investors of August 19 Deadline in Securities Class Action Lawsuit Pivotal Software, Inc. – PVTL appeared first on Wolfe’s Blog.

No Image

Psoriasis Treatment Market to Exhibit 8.2% CAGR, Rising Prescription Volume for Interleukin Inhibitors Segment to Boost Market: Fortune Business Insights

August 16, 2019 Globe Newswire 0

Pune, Aug. 16, 2019 (GLOBE NEWSWIRE) — The increasing prevalence of psoriasis around the world is boosting the global Psoriasis Treatment Market, says Fortune Business Insights in their recent report. The report is titled Psoriasis Treatment Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2025.” According to the report, the market will reach US$ 37,634.2 Mn by 2026 from US$ 18,378.0 Mn in 2018, exhibiting a CAGR of 8.2% between 2018 and 2026.

According to the report prepared by Fortune Business Insights, the TNF inhibitors segment emerged dominant among drug classes. In 2018, the TNF inhibitor segment held 46.3% share in the market. However, in the coming years, the market may witness higher demand for biosimilar version leading to the decline in the price of TNF inhibitors. This, accompanied by the increasing prescription volume for interleukin inhibitors segment may help the interleukin inhibitors to emerge as the dominant segment in the coming years.


Browse Complete Report Details with Table of Content and Figures:

https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600


Rising Prevalence of Plaque Psoriasis to Increase Demand for Treatment, Boosting Market

One of the major factor boosting the global Psoriasis Treatment Market is the increasing prevalence of the disease itself. The World Health Organization states that the prevalence of psoriasis is estimated to vary between 0.09% to 11.0% across all nations. This ultimately means that psoriasis is a serious problem. Psoriasis can occur to anyone irrespective of age but is usually reported to occur to aged people between 50 to 70 years. The rising geriatric population and their vulnerability towards diseases such as psoriatic arthritis are factor propelling growth of the market. These, coupled with the rising prevalence of plaque psoriasis, are likely to create growth opportunities for the market in the forecast period.

The rising availability of biologic and biosimilar products is helping the market for psoriasis grow rapidly. Increase in prescription volume of the biologic products and favorable reimbursement policies by governments are also helping the market grow and continue doing so in the forecast duration as well.

Full story available on Benzinga.com

The post Psoriasis Treatment Market to Exhibit 8.2% CAGR, Rising Prescription Volume for Interleukin Inhibitors Segment to Boost Market: Fortune Business Insights appeared first on Wolfe’s Blog.

No Image

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

August 16, 2019 Globe Newswire 0

MONT-SAINT-GUIBERT, Belgium, Aug. 16, 2019 (GLOBE NEWSWIRE) — Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the Company will report first half 2019 financial results and business highlights on the evening of Thursday, August 22, 2019.

Following the press release, Celyad management will host a conference call on Friday, August 23 at 2pm CEDT / 8am EDT to discuss first half 2019 results and provide an update on the Company’s recent progress and upcoming milestones.

Participants may access the conference call by dialing any of the following numbers:

  Belgium, Brussels +32 (0) 24 01 70 35  
  France, Paris +33 (0)1 76 72 89 28   
  United States: +1 917 720 0181  
  International: +44 (0) 2071 928501  
  Conference ID: 3547725  

To access the subsequent archived recording, visit the “Events & Webcasts” section of the Celyad website.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal …

Full story available on Benzinga.com

The post Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call appeared first on Wolfe’s Blog.

No Image

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

August 16, 2019 Globe Newswire 0

MONT-SAINT-GUIBERT, Belgium, Aug. 16, 2019 (GLOBE NEWSWIRE) — Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the Company will report first half 2019 financial results and business highlights on the evening of Thursday, August 22, 2019.

Following the press release, Celyad management will host a conference call on Friday, August 23 at 2pm CEDT / 8am EDT to discuss first half 2019 results and provide an update on the Company’s recent progress and upcoming milestones.

Participants may access the conference call by dialing any of the following numbers:

  Belgium, Brussels +32 (0) 24 01 70 35  
  France, Paris +33 (0)1 76 72 89 28   
  United States: +1 917 720 0181  
  International: +44 (0) 2071 928501  
  Conference ID: 3547725  

To access the subsequent archived recording, visit the “Events & Webcasts” section of the Celyad website.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal …

Full story available on Benzinga.com

The post Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call appeared first on Wolfe’s Blog.

No Image

Craft 1861 Partners With World Boxing Council To Work On Research, Product Line

August 15, 2019 Alex Oleinic 0

Hemp-derived CBD products manufacturer Craft 1861 said on Thursday it has established a venture with the World Boxing Council. Both parties will work together on research for CBD use in the recovery process and will develop a line of products.
What Hap…

The post Craft 1861 Partners With World Boxing Council To Work On Research, Product Line appeared first on Wolfe’s Blog.

No Image

Port Report: East Coast Notches First-Half Growth For Box Imports

August 15, 2019 FreightWaves 0

Container volumes into U.S. ports slowed through the first half of 2019 due to the overhang from last year’s push to bring in containers ahead of tariffs and the uncertain economic outlook.

Thanks to the trade war with China, trans-Pacific import volumes took the biggest hit.  

The 10 largest U.S. ports by throughput reported loaded imports of 9.96 million twenty-foot equivalent units (TEUs) in the six-month period ending June 30. The year-to-date total represents a growth rate of 2.1 percent.

The West Coast ports of Los Angeles-Long Beach, Seattle-Tacoma and Oakland saw container imports of 5.24 million TEUs from January through June, a 1.8 percent drop over the same period in 2018. 

The Port of Long Beach saw the largest slowdown in container imports, with year-to-date inbound volume of 1.81 million TEUs, a 9 percent decline from the same period in 2018. July saw another month of declining imports into the second-largest port in the U.S. 

Long Beach executive director Mario Cordero said the on-again, off-again tariff fight with China is “hitting the West Coast …

Full story available on Benzinga.com

The post Port Report: East Coast Notches First-Half Growth For Box Imports appeared first on Wolfe’s Blog.

No Image

Macy’s ‘Innovation Ideas’ Are Good But Not Good Enough, Morgan Stanley Says

August 15, 2019 Jayson Derrick 0

Macy’s Inc (NYSE: M) presented to investors new details of a turnaround plan that sounds compelling but not enough to “turn the tide,” according to Morgan Stanley.

The Analyst

Morgan Stanley analyst Kimberly Greenberger maintains an Underweight rating on Macy’s with a price target lowered from $20 to $17.

The Thesis

Macy’s reported second-quarter results, which expanded its total core retail operations losses to $70 million for the first half of 2019, Greenberger wrote in a note. Total operating income dollars were 37% lower year-over-year at $361 million. More concerning is the fact that core retail EBIT dollars in the fourth quarter at $645 …

Full story available on Benzinga.com

The post Macy’s ‘Innovation Ideas’ Are Good But Not Good Enough, Morgan Stanley Says appeared first on Wolfe’s Blog.